New vaccine methods using sublingual delivery to improve acceptance and distribution
Sublingual Supramolecular Vaccines and Immunotherapies
['FUNDING_R01'] · DUKE UNIVERSITY · NIH-10899700
This study is exploring a new way to give vaccines under the tongue to make them easier and less scary for people, especially kids, while also making it simpler to distribute them in places that need them most.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DUKE UNIVERSITY (nih funded) |
| Locations | 1 site (DURHAM, UNITED STATES) |
| Trial ID | NIH-10899700 on ClinicalTrials.gov |
What this research studies
This research focuses on developing innovative vaccine delivery methods that utilize sublingual (under the tongue) administration to enhance patient acceptance and improve global distribution. By creating supramolecular peptide biomaterial vaccines, the project aims to address common issues associated with traditional needle-based vaccinations, such as pain and anxiety, which contribute to vaccine hesitancy. The approach also seeks to eliminate the need for cold-chain storage, making it easier to distribute vaccines in various settings, especially in underserved communities. The research will involve designing and testing these new vaccines to ensure they are effective and safe for use in children and other populations.
Who could benefit from this research
Good fit: Ideal candidates for this research include children aged 0-11 years who may benefit from less invasive vaccination methods.
Not a fit: Patients who are not within the pediatric age range or those who have contraindications to vaccination may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to more widely accepted and easily distributed vaccines, ultimately improving vaccination rates and public health outcomes.
How similar studies have performed: Other research has shown promise in alternative vaccine delivery methods, but this specific approach using supramolecular biomaterials is relatively novel.
Where this research is happening
DURHAM, UNITED STATES
- DUKE UNIVERSITY — DURHAM, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: COLLIER, JOEL H — DUKE UNIVERSITY
- Study coordinator: COLLIER, JOEL H
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Autoimmune Diseases